Experts Say US Aid Cuts May Limit Access to Injectable HIV Prevention Drug
The Guardian · July 31, 2026Original source ↗
What happened
At the AIDS 2026 Conference in Rio de Janeiro, experts discussed the potential of lenacapavir, an injectable HIV prevention drug, to reduce new HIV cases. However, they indicated that recent cuts in US foreign aid may hinder access to this medication for those in need.
Why it matters
The availability of effective HIV prevention measures is crucial for global public health efforts.
How this story affects people
How does this story affect you if you are a patient?
Patients at risk of HIV may find it harder to access lenacapavir due to funding cuts, potentially increasing their risk of infection.
How does this story affect you if you are a parent?
Parents of adolescents and young adults may be concerned about limited access to effective HIV prevention methods, which could affect their children's health.
How does this story affect you if you are a retiree?
Retirees who are at risk for HIV may face challenges in accessing preventive treatments like lenacapavir, especially if funding cuts lead to reduced healthcare services.
Want this written about you?
The breakdown above is the shared version, for kinds of people. In the app, Ripple uses your job, your city, and your family, then writes that part about you.
Get your Ripple